Clinical Trial Search

Primary: Hemagglutination Inhibition (HI) Antibody Titers Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of High-Dose…

Primary: Asparaginase-Related Toxicity Rate — 26; 28 percentage of participants — p=.60

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1 — 0; 0 Participants

Primary: Number of Participants With Solicited Adverse Events — 2; 5; 9; 9 Participants

Primary: Safety and Tolerability — 28; 21; 0; 0 participants

Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants

Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea

Primary: Change From Baseline to Peak Salivary Cortisol Level — 2.9; 4.3; 3.3 Number (ratio of peak to baseline)

Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51

Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events

Primary: Number of Environmentally-implicated Healthcare-Associated Infections (eiHAIs) Associated With the Additional Use of a PX-UV Disinfection Compared to Standard Terminal…

Primary: Number of Participants Whose Anti-HEV Antibody Seroconverted at One Month After The Third Dose — 188; 196 Participants

Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants

Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21

Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants